Editas Medicine to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT) announced that management will participate in two September investor conferences: the Wells Fargo Healthcare Conference on September 8, 2026 at 4:30 p.m. ET in Boston, and the Cantor Global Healthcare Conference on September 10, 2026 at 3:55 p.m. ET in New York.
Both appearances will be fireside chats, with live webcasts and 30-day replays available via the company’s investor relations website.
Details
News Market Reaction – EDIT
On Sep 1, the day this news came out, EDIT closed 0.33% above the previous close. Our momentum scanner recorded 8 alerts in the available session data.
Data tracked by StockTitan Argus for the Sep 1 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:
- Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA
- 2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY
To access the live webcast of Editas Medicine’s Fireside Chats, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.